Efficacy and Safety of Adintrevimab (ADG20) for the Treatment of High-Risk Ambulatory Patients With Mild or Moderate COVID-19: Results From a Phase 2/3, Randomized, Placebo-Controlled Trial (STAMP) Conducted During Delta Predominance and Early Emergence of Omicron
Authors:
Open Access
- 24 May 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (6) , ofad279
Abstract
Safe and effective treatments are needed to prevent severe outcomes in individuals with coronavirus disease 2019 (COVID-19). We report results from STAMP, a phase 2/3, multicenter, double-blind, randomized, placebo-controlled trial of adintrevimab, an extended half-life monoclonal antibody, for treatment of high-risk ambulatory patients with mild to moderate COVID-19. Nonhospitalized, unvaccinated participants aged ≥12 years with mild to moderate COVID-19 and ≥1 risk factor for disease progression were randomized to receive a single intramuscular injection of 300 mg adintrevimab or placebo. Enrollment was paused due to the global emergence of the Omicron BA.1/BA1.1 variants, against which adintrevimab showed reduced activity in vitro. The primary efficacy endpoint was COVID-19–related hospitalization or all-cause death through day 29 in participants with COVID-19 due to laboratory-confirmed or suspected non-Omicron severe acute respiratory syndrome coronavirus 2 variants. Between 8 August 2021 and 11 January 2022, 399 participants were randomized to receive adintrevimab (n = 198) or placebo (n = 201), including 336 with COVID-19 due to non-Omicron variants. COVID-19–related hospitalization or all-cause death through day 29 occurred in 8 of 169 (4.7%) participants in the adintrevimab group and 23 of 167 (13.8%) participants in the placebo group, a 66% relative risk reduction in favor of adintrevimab (standardized risk difference, −8.7% [95% confidence interval, −14.71% to −2.67%]; P = .0047). Incidence of treatment-emergent adverse events (TEAEs) was similar between treatment groups (33.9% for adintrevimab and 39.5% for placebo). No adintrevimab-related serious TEAEs were reported. Treatment with a single intramuscular injection of adintrevimab provided protection against severe outcomes in high-risk ambulatory participants with COVID-19 due to susceptible variants, without safety concerns. Clinical Trial Registration. NCT04805671.Keywords
This publication has 10 references indexed in Scilit:
- Safety, Pharmacokinetics, Serum Neutralizing Titers, and Immunogenicity of Adintrevimab, a Monoclonal Antibody Targeting SARS-CoV-2: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Dose-escalation Study in Healthy AdultsInfectious Diseases and Therapy, 2023
- Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titersScience Translational Medicine, 2023
- Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19New England Journal of Medicine, 2021
- Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patientsBMC Infectious Diseases, 2021
- Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serumCell, 2021
- ADME and Pharmacokinetic Properties of Remdesivir: Its Drug Interaction PotentialPharmaceuticals, 2021
- Antibody evasion by the P.1 strain of SARS-CoV-2Cell, 2021
- Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibodyScience, 2021
- SARS-CoV-2 detection, viral load and infectivity over the course of an infectionJournal of Infection, 2020
- Broad neutralization of SARS-related viruses by human monoclonal antibodiesScience, 2020